Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3327-3332

  Takashima, Kazuhiro ^a   Fujiwara, Hitoshi ^a   Inada, Satoshi ^a   Atsuji, Kiyoto ^a   Araki, Yasunobu ^a   Kubota, Takeshi ^a   Yamagishi, Hisakazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Adoptive immunotherapy; GFP; Green mice; LAK cells

Indexed keywords

GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ERYTHROCYTE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HAIR; LUNG METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPLEEN;

ANIMALS; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; SPLEEN; SURVIVAL RATE;

EID: 33750693922     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mule JJ, Shu S, Schwarz SL and Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487-1489, 1984.
2. Nannmark U, Basse P, Johansson BR, Kuppen P, Kjargaard J and Hokland M: Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumor-bearing animals. Nat Immunol 15: 78-86, 1996.
3. Chalfie M, Tu Y, Euskirchen G, Ward WW and Prasher DC: Green fluorescent protein as a marker for gene expression. Science 263: 802-805, 1994.
4. Okabe M, Ikawa M, Kominami K, Nakanishi T and Nishimune Y: 'Green mice' as a source of ubiquitous green cells. FEBS Letters 407: 313-319, 1997.
5. Alexander RB and Rosenberg SA: Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunol 145: 1615-1620, 1990.
6. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB and Gorelik E: Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142: 1748-1754, 1989.
7. Gautam SC, Chikkala NF, Lewis I, Grabowski DR, Finke JH and Ganapathi R: Efficacy of interleukin-2 activated killer cells against adriamycin resistant mouse B16-BL6 melanoma. Anticancer Res 12: 921-926, 1992.
8. Guttinger M, Guidi F, Chinol M, Reali E, Veglia F, Paganelli G, Corti A and Siccardi AG: Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 60: 4211-4215, 2000.
9. Allavena P, Damia G, Colombo T, Maggioni D, D'incalci M and Mantovani A: Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell line resistant to antitumor agents. Cell Immunol 120: 250-258, 1989.
10. Lafreniere R and Rosenberg SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45: 3735-3741, 1985.
11. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K and Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
12. Kjargaad J, Hokland ME, Agger R, Skovbo A, Nannmark U and Basse PH: Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother 48: 550-560, 2000.
13. Skitzki J, Craig RA, Okuyama R, Knibbs RN, McDonagh K, Chang AE and Stoolman LM: Donor cell cycling, trafficking and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 64: 2183-2191, 2004.
14. BAR MH, Sznol M and Atkins MB: Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 8: 1138-1147, 1990.
15. Brubaker J, Chong K and Welsh R: Lymphokine-activated killer cells are rejected in vivo by activated natural killer cells. J Immunol 147: 1439-1444, 1991.
16. Ames IH, Gagne GH, Garcia AM, John PA, Scatorchia GM, Tomar RH and McAfee JG: Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice. Cancer Immunol Immunother 29: 93-100, 1989.
17. Felgar R and Hiserodt JC: In vivo migration and tissue localization of highly purified tymphokine activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol 129: 288-298, 1990.
18. Ratner S: Lymphocytes stimulated with recombinant human interleukin-2: Relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice. J Natl Cancer Inst 82: 612-616, 1990.
19. Schäfer E, Dummer R, Eilles C, Börner W, Martini R, Rendl J and Burg G: Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma. Eur J Nucl Med 18: 106-110, 1991.
20. Eberlein TJ, Rodrick ML, Massaro AF, Jung SE, Mannick JA and Schoof DD: Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Immunol Immunother 30: 145-150, 1989.
21. Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK and McKnight JE: Intraperitoneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 10: 1618-1629, 1990.
22. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
23. Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lotzova E and Bolhuis R: Lymphokine activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8: 178-181, 1987.
24. Barth RJ, Bock SN, Mule JJ and Rosenberg SA: Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 144: 1531-1537, 1990.
25. Melder RJ, Brownell AL, Shoup TM, Brownell GL and Jain RK: Imaging of activated natural killer cells in mice by positron emisson tomography; preferential uptake in tumors. Cancer Res 53: 5867-5871, 1993.
26. Wallance PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC and Muirhead KA: Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res 53: 2358-2367, 1993.
27. Ettinghausen SE and Rosenberg SA: Immunotherapy of murine sarcoma using lymphokine activated killer cells. Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 48: 2784-2792, 1986.
28. Lafreniere R and Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine-activated killer (LAK) cells and recombinant inteleukin-2 can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135: 4273-4280, 1985.
29. Teare GF, Horan PK, Slezak SE, Smith C and Hay JB: Long-term tracking of lymphocytes in vivo. The migration of PKH-labeled lymphocytes. Cell Immunol 134: 157-170, 1991.
30. Yan JC, Perry-Lalley D and Rosenberg SA: An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Modif 2: 149-159, 1990.
31. Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY and Rosenberg SA: In vivo distribution of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709-1711, 1989.
32. Alexander RB and Rosenberg SA: In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunother 10: 120-130, 1991.